Jennifer M Vittorio

Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.; Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Hassenfeld Children's Hospital at NYU Langone, New York, New York, USA.

11 publications 2016 – 2024 ORCID

Research Overview

Jennifer M. Vittorio researches pediatric liver disease and transplantation, focusing on improving outcomes for children and young adults. Her work spans genetic liver disorders, transplant immunology, and the critical challenge of transitioning young patients from pediatric to adult care. She has demonstrated that living donor transplants — especially from mothers — offer lasting immunologic advantages, and has helped establish quality frameworks for pre-transplant care.

Publications

The use of once-daily LCP-Tacrolimus with adolescent and young adult solid organ transplant recipients.

2024

Pediatric transplantation

Householder S, Ramakrishnan A, Chen JK, Gorsch L, Tsapepas D +3 more

Plain English
This study tested whether a once-daily tacrolimus formulation (LCP-tacrolimus) improved medication adherence in young transplant patients aged 12 and up, who are known to struggle with daily medications. Switching to the once-daily version showed numerically better adherence by both provider assessment and a standard measurement tool, though the improvements did not reach statistical significance — likely because the group was too small. The drug was safe and effective, but did not reduce pill burden and sometimes cost more, so it may be best suited for carefully selected patients.

View on PubMed

Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.

2024

Hepatology (Baltimore, Md.)

Brahmania M, Kuo A, Tapper EB, Volk ML, Vittorio JM +26 more

Plain English
A liver disease specialist committee developed 41 quality measures covering the entire pre-transplant journey — from when a doctor first refers a patient through organ acceptance — to reduce variation in how transplant centers evaluate and list patients. The measures span structure, process, and outcomes, with patients rating "understanding the transplant process" as most important. This framework gives transplant programs a concrete tool for local quality improvement that goes beyond what's already tracked for regulatory reporting.

View on PubMed

The diagnostic yield of exome sequencing in liver diseases from a curated gene panel.

2023

Scientific reports

Kong XF, Bogyo K, Kapoor S, Shea PR, Groopman EE +16 more

Plain English
Researchers analyzed genetic data from 758 patients with chronic liver disease, looking for mutations in 502 genes linked to inherited liver conditions. After careful filtering, they found a definitive genetic diagnosis in 5.7% of patients — a meaningful number given that many of these conditions have specific treatment implications, including family screening and preventive care. The study shows that exome sequencing can uncover inherited causes of liver disease, but requires multiple rounds of expert review to avoid false results.

View on PubMed

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.

2023

JHEP reports : innovation in hepatology

Thompson RJ, Artan R, Baumann U, Calvo PL, Czubkowski P +36 more

Plain English
This open-label extension study followed children and new patients with progressive familial intrahepatic cholestasis treated with odevixibat, a pill that blocks bile acid recycling in the gut. Across all patient groups, the drug sustained reductions in blood bile acid levels and reduced itching over 24 weeks, with most side effects being mild. The results support odevixibat as a well-tolerated option that addresses both the biochemical and quality-of-life burden of this severe inherited liver disease.

View on PubMed

Current approach to health care transition and integration into adult care for pediatric liver transplant recipients: A call for partnership.

2023

Clinical transplantation

King LY, Kosmach-Park B, Parish A, Niedzwiecki D, Jackson WE +1 more

Plain English
Surveys of 40 pediatric and 79 adult liver transplant programs revealed a major gap: pediatric centers are far more likely to have formal transition policies, clinics, and readiness tools than adult centers, even though young patients are at high risk for rejection and graft loss during the handoff period. Both sides agreed on the key barriers — patients who disengage, missed appointments, and limited staff. The authors call for structured partnerships between pediatric and adult teams to close this gap.

View on PubMed

Risk Factors for 30-Day Unplanned Readmission After Hepatectomy: Analysis of 438 Pediatric Patients from the ACS-NSQIP-P Database.

2021

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Kang E, Shin JI, Griesemer AD, Lobritto S, Goldner D +3 more

Plain English
Using a national surgical database of 438 children who had liver resections, researchers found that 14.6% were readmitted within 30 days — a rate driven mainly by organ-space surgical site infections, which independently tripled the odds of readmission. Children with active cancer, gastrointestinal disease, or nutritional support needs were also more likely to come back. Targeting infection prevention after pediatric liver surgery could meaningfully cut readmissions and the costs that come with them.

View on PubMed

Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease.

2020

Diabetes care

Vittorio JM, Lavine JE

View on PubMed

Management of Wilson Disease Diagnosed in Infancy: An Appraisal of Available Experience to Generate Discussion.

2020

Journal of pediatric gastroenterology and nutrition

Valentino PL, Roberts EA, Beer S, Miloh T, Arnon R +2 more

Plain English
Genetic testing is increasingly identifying Wilson disease — a copper metabolism disorder — in infants and even before birth, long before the condition causes symptoms. Because there is almost no published guidance on managing babies diagnosed this way, the authors present a case and propose a stepwise treatment algorithm based on the physiology of copper in early development. Their goal is to start a conversation among specialists and build evidence-based best practices for this emerging clinical situation.

View on PubMed

Roux-en-Y enterolith leading to obstruction and ischemic necrosis after pediatric orthotopic liver transplantation.

2018

Pediatric transplantation

Quillin RC, Bongu A, Kasper V, Vittorio JM, Martinez M +3 more

Plain English
A 12-year-old liver transplant recipient presented with fever and abdominal pain 11 years after transplant, and was found to have a stone obstructing and killing a section of his surgically reconstructed bowel. The stone had formed in the Roux limb of his biliary reconstruction — a rare but serious complication that can look like bowel obstruction or bile duct infection. Surgeons removed the affected bowel and rebuilt the connection, and the case highlights that transplant surgeons should consider bile-derived stones when evaluating abdominal emergencies in long-term transplant patients.

View on PubMed

Durable Clinical and Immunologic Advantage of Living Donor Liver Transplantation in Children.

2018

Transplantation

Przybyszewski EM, Verna EC, Lobritto SJ, Martinez M, Vittorio JM +5 more

Plain English
In a retrospective study of 241 children who survived at least one year after liver transplantation, those who received a liver from a living donor (usually a parent) had significantly lower rates of rejection, less need for immunosuppression, and better graft survival than those who received a deceased donor liver. Livers from mothers outperformed fathers, with lower rejection and lymphoma rates — possibly because of immune tolerance developed during pregnancy. The findings make a strong case for greater use of living donor transplantation in children.

View on PubMed

Anakinra-Induced Acute Liver Failure in an Adolescent Patient with Still's Disease.

2016

Pharmacotherapy

Taylor SA, Vittorio JM, Martinez M, Fester KA, Lagana SM +2 more

Plain English
Anakinra, an anti-inflammatory drug used to treat certain autoimmune conditions, caused acute liver failure in a teenage boy being treated for adult-onset Still's disease. The liver failure resolved when the drug was stopped. While liver toxicity from anakinra had been reported in adults, this appears to be the first documented case of severe acute liver failure in an adolescent, underscoring the need to monitor liver function closely in any patient on this medication.

View on PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.